The method is based on the observation that the affinity of the cyclic nucleotide antibodies for the 2-0-succinyl or acetyl derivatives is considerably greater than that for the nonacylated cyclic nucleotides. Morgan AJ, Murray KJ, Chaliss RA (1993) Comparison of the effect of isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels in SH-SY5Y neuroblastoma cells. A simple and rapid method for a highly sensitive radioimmunoassay of cyclic AMP and GMP is described. Marini P, Cascio MG, King A et al (2013) Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB 2 receptors. Curr Neuropharmacol 16:959–970īrennecke B, Gazzi T, Atz K et al (2021) Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. Rapino C, Tortolani D, Scipioni L, Maccarrone M (2018) Neuroprotection by (endo)cannabinoids in glaucoma and retinal neurodegenerative diseases. Br J Pharmacol 158:382–391īolognini D, Cascio MG, Parolaro D et al (2012) AM630 behaves as a protean ligand at the human cannabinoid CB 2 receptor. Mancini I, Brusa R, Quadrato G et al (2009) Constitutive activity of cannabinoid-2 (CB 2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. McGuinness D, Malikzay A, Visconti R et al (2009) Characterizing cannabinoid CB 2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay. Yang R, Fredman G, Krishnamoorthy S et al (2011) Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. Gonsiorek W, Lunn C, Fan X et al (2000) Endocannabinoid 2-arachidonoyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Cannabinoid receptors and their ligands: beyond CB 1 and CB 2. Pertwee RG, Howlett AC, Abood ME et al (2010) International Union of Basic and Clinical Pharmacology.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |